Healthcare - Biotechnology - NASDAQ - CH
$ 48.83
-6.99 %
$ 3.08 B
Market Cap
-38.45
P/E
CASH FLOW STATEMENT
-42.8 M
OPERATING CASH FLOW
-25.2 M
INVESTING CASH FLOW
480 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
MoonLake Immunotherapeutics
| Net Income | -44.1 M |
| Depreciation & Amortization | 13.2 K |
| Capital Expenditures | -285 K |
| Stock-Based Compensation | 7.11 B |
| Change in Working Capital | -6.22 M |
| Others | -7.1 B |
| Free Cash Flow | -43.1 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (44.1) | (64.5) | (53.6) | 90.8 K |
| Depreciation & Amortization | 13.2 K | 12.4 K | 4.97 K | 0 |
| Deferred Income Tax | 0 | 0 | 1.4 | 0 |
| Stock Based Compensation | 7 106.0 | 9.65 K | 10.9 K | 0 |
| Other Operating Activities | (7 098.5) | 0.4 | 12.6 | 9.92 K |
| Change in Working Capital | (6.2) | (1.4) | 4.5 | (0.2) |
| Cash From Operations | (42.8) | (55.9) | (35.2) | (0.3) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | (0.3) | 16 K | 50.7 K | 0 |
| Other Items | (24.9) | (32.3) | 0 | (115.0) |
| Cash From Investing Activities | (25.2) | (32.3) | 50.7 K | (115.0) |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 6.2 K | 0 |
| Total Debt Repaid | 0 | (15.0) | 15.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.8) | 134.7 | 0 | (0.3) |
| Cash From Financing Activities | 479.7 | 119.7 | 43.3 | 116.7 |
| CHANGE IN CASH | ||||
| Net Change In Cash | 411.7 | 31.5 | 6.7 | 1.3 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (43.1) | (55.9) | (35.2) | (0.3) |